Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022
SAN DIEGO, May 23, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data on the use of INGREZZA® (valbenazine) capsules for the treatment of tardive dyskinesia (TD) at the American Psychiatric Association (APA) Annual Meeting being held in person May 21-25 in New Orleans and virtually June 7-10.
Neurocrine Biosciences, the leading neuroscience-focused company in the treatment of TD, will present findings from a post hoc analysis of two long-term studies of INGREZZA evaluating global TD improvement and stability of psychiatric symptoms (Poster title: Poster #P7-088 Global Improvements and Psychiatric Stability in Adults with Tardive Dyskinesia: Post Hoc Analyses of Two Long-Term Valbenazine Studies). The analysis found that long-term treatment (48 weeks) for TD with once-daily INGREZZA (40 mg or 80 mg) resulted in substantial clinician-rated and self-rated global improvements of TD symptoms while stability of psychiatric symptoms was maintained, regardless of the participant's primary psychiatric condition.
"The findings presented at the APA Annual Meeting provide further insight into aspects of tardive dyskinesia management that are important to patients," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. "Treatment of TD symptoms often requires consideration of complex psychiatric conditions. These data demonstrate that stability of psychiatric symptoms is maintained during TD treatment with valbenazine."
Additional presentations include:
A full list of all abstracts being presented by Neurocrine Biosciences at the 2022 APA Annual Meeting is available in the poster proceedings on the Annual Meeting Website.
About Tardive Dyskinesia (TD)
About INGREZZA® (valbenazine) Capsules
INGREZZA is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function, helping to regulate nerve signaling in adults with tardive dyskinesia. VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons. INGREZZA, developed by Neurocrine Biosciences, is novel in that it selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic, or muscarinic receptors. Additionally, INGREZZA can be taken for the treatment of tardive dyskinesia as one capsule, once-daily, together with most psychiatric medications such as antipsychotics or antidepressants.
INGREZZA® (valbenazine) capsules is a prescription medicine used to treat adults with movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).
It is not known if INGREZZA is safe and effective in children.
Important Safety Information
Do not take INGREZZA if you:
INGREZZA may cause serious side effects, including:
o fast, slow, or irregular heartbeat
Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you faint.
Before taking INGREZZA, tell your healthcare provider about all of your medical conditions including if you: have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effect of INGREZZA is sleepiness (somnolence). Other side effects include changes in balance (balance problems, dizziness) or an increased risk of falls, headache, feelings of restlessness, dry mouth, constipation, and blurred vision.
These are not all of the possible side effects of INGREZZA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
About Neurocrine Biosciences
The Neurocrine logo, and INGREZZA are registered trademarks of Neurocrine Biosciences, Inc.
©2022 Neurocrine Biosciences, Inc. All Rights Reserved. CP-TD-US-1162 05/2022
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-ingrezza-valbenazine-data-on-tardive-dyskinesia-improvement-and-stability-of-psychiatric-symptoms-at-american-psychiatric-association-annual-meeting-2022-301552333.html
SOURCE Neurocrine Biosciences, Inc.
Company Codes: NASDAQ-NMS:NBIX